Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $320 to $316.
Morgan Stanley Maintains Overweight on United Therapeutics, Lowers Price Target to $316
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.